Partitionbiotm Awarded Grant To Exploit Its Novel Biologics Shuttle Platform For Therapeutic Nucleic Acids Delivery
Date
6/17/2024 8:47:19 AM
(MENAFN- PR Newswire)
CAMBRIDGE, England, June 17, 2024 /PRNewswire/ -- PartitionBio TM
received a grant from the Bill & Melinda Gates Foundation to utilise its proprietary biocondensate-based macromolecule delivery platform for the transfection of cells with nucleic acids. The purpose of the project is to deploy the breakthrough technology as a novel non-viral tool for the introduction of protein-encoding RNA or DNA into human cells. The long-term aim of the work is to enable a more efficient approach for the expression of therapeutic proteins in patients.
About PartitionBioTM
PartitionBio TM
is a Cambridge (UK) based biotech start-up company offering a revolutionary technology platform for the non-viral delivery of a broad spectrum of macromolecules with therapeutic potential across the cell membrane. Possible payloads for the shuttle condensates include antibodies, proteins, peptides and nucleic acids.
Contact:
Helen Kent-Armes
[email protected]
07747 806 905
SOURCE PartitionBio
MENAFN17062024003732001241ID1108341260
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.